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INTRODUCTION
Hyponatraemia is one of the commonest biochemical
abnormalities encountered in the general hospitalized
population with an incidence of 1%.1,2 Hyponatraemia is
defined  as serum sodium level of less than 135 mmol/L
and severe hyponatraemia as level less than 120
mmol/L.3 Hyponatraemia particularly in its milder forms
may be a reflection of non-specific illness so it is also
called the “biochemical ESR”4 assuming importance due
to the associated mortality and morbidity.5,6 On the
converse, many believe that the mortality and morbidity
associated with hyponatraemia may be due to the
associated cardiac, pulmonary, hepatic, neurological
and renal conditions rather than the electrolyte
imbalance alone and may actually reflect the severity of
the primary illness.5,7 Making an accurate diagnosis  and
instituting appropriate therapy, therefore, may be
crucial.
Despite being one of the commonest electrolyte
imbalances, there have been problems in both the
management and treatment of this condition. Mild
hyponatraemia may be asymptomatic, with presentation
varying from confusion to hallucinations, agitation and
coma. History and physical examination needs to be
accompanied by relevant biochemical profile as the
treatment given depends on the underlying cause.
If hyponatraemia is inadequately investigated, the
management  instituted may actually be inappropriate
and inadequate. Having all these factors in mind, the
purpose of this study was to determine the aetiology,
treatment and outcome of hyponatraemia  in patients
hospitalized at a tertiary care hospital during a certain
period. 
METHODOLOGY
It was a case series study, which included all adult
patients ≥ 15 years admitted to the Aga Khan University
Hospital, Karachi under the medical services from
January to June 2004 with serum sodium level of ≤ 130
mmol/L on admission. Patients’ records were reviewed
for information such as age, gender, signs and
symptoms related to hyponatraemia on admission,
assessment of volume status (hypovolaemic,
euvolaemic or hypervolaemic) according to clinical
assessment based on presence or absence of
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tachycardia, postural hypotension, dry mucous
membranes, peripheral oedema, raised JVP, pulmonary
oedema, ascites and substantiated with determination
of blood urea and serum creatinine values. Serum
sodium (Na) levels were noted on admission and at
24 and 48 hours. Final Na level (which may be last Na
level checked during admission or Na prior to discharge)
was also noted. Simultaneous  plasma glucose was also
noted and sodium levels were corrected accordingly if
glucose levels were >100 mg/dl. The formula used for
correction was 1.5 mmol/L increment in sodium level for
each 90 mg/gl1 rise in glucose above 100 mg/l. Serum
potassium, chloride  and  bicarbonate levels were noted
on admission. Urine and plasma (measured and
calculated) osmolality, urinary spot sodium and urine
specific gravity was noted wherever available. Similarly,
a note of thyroid function tests, cortisol (random and/or
after short Synacthen test), Liver Function Tests (LFTs)
and lipid profile was made. Maintenance of fluid
balance charts, treatment received, be it fluid restriction,
intravenous fluids (with type of fluid) or a combination
of both, with and without use of Oral Rehydration
Solution (ORS) was noted. Other associated comorbid
conditions, duration of stay and outcome were also
noted. A sodium level of ≤ 120 mmol/L would be
rechecked and reported to the ward.
Data was analysed by SPSS version 11. Values were
expressed as mean + standard deviation (SD).
Significance was analysed by students t-test and
p-values <0.05 were considered to be significant.
RESULTS
Over a 6-month period, 220 patients ≥ 15 years of age
were admitted to the medical services with serum
sodium on admission of ≤ 130 mmol/L. There were 127
females and 93 males. The mean age was 65 ± 13.29
years, which ranged  from 15 to 98 years. The mean
sodium on admission was 119.46 mmol/L with a range
of 101 to 130 mmol/L. Over half (53%) patients were in
the range of 120-130 mmol/L, 34.5% (76) were in the
range of 110-119  mmol/L and smaller numbers (12%)
were in the range of 100-109 mmol/L. Serum sodium
was checked in 187 patients after 24 hours and 141 had
their serum sodium checked after 48 hours as well.
One hundred and sixteen patients had serum sodium
checked beyond 48 hours. A quarter of patients
presented with symptoms suggestive of cerebral
oedema/cortical dysfunction. Of those, 61% had
drowsiness, 35% had weakness and irritability was seen
in 4%. However, it could not be ascertained whether the
symptoms were due to hyponatraemia alone or due to
other medical conditions. For those patients, serum
sodium levels on admission were similar to the study
group and 11% had serum sodium levels between 100-
109 mmol/L.
Most of the patients (201) received intravenous (IV)
fluids. Six patients were placed on fluid restriction alone
and 132 on intravenous fluids alone. Sixty patients
received intravenous fluids and had free fluid restriction.
Six patients were on a combination of fluid restriction,
IV fluids and ORS.10 Patients received diuretics, while
they were stopped in one patient. However, 3 patients
received no treatment for their hyponatraemia.
Of the patients receiving intravenous fluids, 145 (66%)
received normal saline followed by Ringers lactate
solution given to 9 patients (4%), 3% saline to 3 patients
and 0.45% saline was given to one patient. Dextrose
and dextrose saline were given to 6% and 1.8% patients
respectively.
The rate of correction was >10 mmol/L in 17% in the first
24 hours, however, it was 4.5% in the subsequent 24
hours. This has been summarized in Table I.
Of the patients who had a rate of correction of >10
mmol/L there were 4 mortalities. Three of those patients
had initial sodium level between 110-120 mmol/L and
one patient had serum sodium level of 125 mmol/L.
The duration of stay ranged from less than 24 hours to
27 days with mean of 4 days. 
Mortality was seen in 15 (6.8%) patients. Mean duration
of stay in the expired patients was  7.7 days. Four left
against medical advice, one was shifted to another
hospital and the rest were discharged home.  Infection
was the leading cause of mortality found in 7 (46%)
patients, malignancy (40%) and cardiac and metabolic
causes in 4% patients each. 
In patients who did not survive, half had corrected serum
sodium level on admission between 110-119 mmol/L, 2
had initial values between 100-109 mmol/L and 5 patients
had serum sodium levels between 120-130 mmol/L.
Most patients had more than one cause for their
hyponatraemia. Therefore, they were divided into major
attributer and minor factor for hyponatraemia
summarized in Table II. 
Among the drug induced category of causes, almost
one-third of those patients were on diuretics and another
one third were on ACE inhibitors. ARBs, Selective
Serotonin Release Inhibitors (SSRIs), carbamazepine
and other anti-depressants were being caused in the
rest. 
Thyroid function tests were done in 104 patients.
Adrenal axis was checked in 57 patients with a short
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Table I:  Rate of correction of hyponatraemia in the first 24 hours and
the subsequent 48 hours.
Rate of correction Initial 24 hours Subsequent 48 hours
>15 mmol/L 17 (7.7%) 4 (1.8%)
10-15 mmol/L 21 (9.5%) 6 (2.7%)
5-10 mmol/L 63 (28.6%) 48 (21.8%)
0-5 mmol/L 59 (26.8%) 57 (25.9%)
No improvement 27 (12.3%) 26 (11.8%)
Synacthen test and or a random cortisol level. Spot
sodium determination was done in 116 patients and
urine osmolality was checked in 112 patients. LFTs
were conducted in 109 and lipid profile was obtained in
19 patients. Fluid balance charts were maintained in
all patients. Most of the patients (58.6%) were
euvolaemic, 33.2% were hypovolaemia and 8.6% were
hypervolaemic.
SIADH was found in 6% (13) patients. Four  were
labelled as having SIADH by the treating physicians.
The other 9 had laboratory evidence of SIADH and
fulfilled the diagnostic criteria for this condition. There
were another 7 who had biochemical profile suggestive
of SIADH but did not have either thyroid function tests or
cortisol levels to fulfill the criteria entirely.
DISCUSSION
In this study, a quarter of patients presented with
neurological symptoms though their initial sodium
concentrations were not different from the rest of the
group. In such a retrospective study, it is difficult to
ascertain whether the neurological symptoms were due
to the underlying illness or by hyponatraemia alone or by
a combination of both. The severity of symptoms and
signs of hyponatraemia depend not only on the degree
of sodium depletion but also on the rapidity of fall of
plasma sodium. Patients with mild hyponatraemia
(sodium upto 130 mmol/L) are almost always
asymptomatic. Serum sodium levels between 125-130
mmol/L may be associated with anorexia, nausea,
vomiting and abdominal cramps. Severe
hyponatraemia,  with serum sodium level less than 125
mmol/L may cause neurological symptoms including
agitation, confusion and hallucinations. With levels of
sodium less than 115 mmol/L, there is the risk of
seizures and coma.8
Hyponatraemia of rapid onset is associated with
cerebral oedema raised intracranial pressure and
subsequent decrease in cerebral blood flow leads to
cerebral symptoms.9 In contrast, chronic hyponatraemia
i.e > 48 hours duration allows  slow adaptation to the low
plasma osmolality and, therefore, prevention of cerebral
oedema.10 There remains a controversy whether stable
severe hyponatraemia is associated with brain damage.
In this study, patients who had expired had lower initial
serum sodium levels and longer mean duration of stay
in hospital. 
It was observed that investigations were not done
sequentially and serum osmolality was not matched with
urine osmolality and spot urine sodium. Moreover, the
latter two were checked in upto 50% patients only. The
diagnosis of SIADH needs certain criteria to be fulfilled,
which include  hyponatraemia with hypo-osmolality and
excessive renal sodium excretion in an euvolaemic
patient with normal thyroid and adrenal function.11
Cortisol and thyroid function tests were not done in 7
patients in whom there was a strong suspicion of SIADH
while in this study, charts were well-maintained in all
patients. Previous studies have reported fluid balance
chart maintenance as low as 17% and 40% only.12,13
Hyponatraemia is known to occur more frequently in the
elderly as seen in this study.12-14 The aetiology of
hyponatraemia was most definitely multifactorial with GI
losses accompanied by use of diuretics and ACE I
inhibitors topping the list. Ageing is associated with
reduced cardiac and renal reserve and a reduced ability
to compensate for fluctuations in environmental
conditions. In many cases, this may be coupled with
iatrogenic causes such as the use of diuretics or
medicine which impair the intake of food and fluid. Use
of diuretics being one of the major causes of
hyponatraemia, has also been reported by Saeed13 and
Crook.12
Prior to treatment, the volume status of the patient
needs to be assessed.15 Broadly speaking for
hypovolaemic patients, diuretics need to be stopped and
the intravascular volume be restored with normal saline.
For normovolaemic patients, hypothyroidism and
glucocorticoid deficiency are to be excluded with
restricted fluid intake. Demeclocycline should be
considered for SIADH. For hypervolaemic patient, there
is a need to treat the underlying condition whether it may
be cardiac, hepatic or renal. These patients need salt
and water restriction and diuretics may also be
considered. Asymtomatic hyponatraemia may not
require treatment with hypertonic saline, especially if
sodium levels are greater than 120 mmol/L. Fluid
restriction may be beneficial though the rate of increase
in sodium level is slow at upto 1.5 mmol/L/24 hours.4
Patients with an underlying cause should be treated
for the primary cause. On the contrary, patients with
symptomatic hyponatraemia need hypertonic saline.
Mortality and morbidity associated with treatment with
fluid restriction has been high.16
Normal saline was administered to most of the patients,
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Table II:  The major and minor causes of hyponatraemia in the studied
group.
Major cause (No./%) Minor cause (No./%)
Medicines 66 (30%) 87 (40%)
Gastrointestinal loss 55 (25%) 3 (1.4%)
Chest infection 24 (11%) 6 (2.7%)
Depletional 22 (10%) 22 (10%)
SIADH 13 (6%) -
Malignancy 11 (5%) 5 (2.3%)
Congestive cardiac failure 11 (5%) 1 (0.5%)
Chronic liver disease 8 (3.6%) 1 (0.5%)
Hypothyroidism 6 (2.7%) -
Psychogenic polydipsia 5 (2.3%) -
Panhypopituitarism 2 (0.9%) -
Addison’s disease 1 (0.5%) -
Chronic renal failure 1 (0.5%) 1 (0.5%)
Unknown 4 (1.8%) -
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however, those with chronic liver disease received 5%
dextrose, which is isotonic and acts like pure water due
to the rapid clearance of dextrose. It can be detrimental
to patients with severe hyponatraemia. The prevalence
of hyponatraemia in patients with decompensated
cirrhosis may be upto 48%.17,18 Patients with congestive
heart failure and cirrhosis have diminished “effective”
circulatory volume and, therefore, increased levels of
ADH.19 Treatment of hyponatraemia in these patients
is, therefore, difficult and not always adequate. The
mainstay of treatment in such patients being fluid
restriction and  use of diuretics by improvement in the
intravascular reserve. In SIADH, the first line treatment
is fluid restriction. Isotonic saline has a limited role in
SIADH as the urine osmolality is >300 mOsmol/kg  H2O
and the osmolality of fluid administered should be
greater than the urine osmolality.19 Demeclocycline is
the treatment of choice for treatment of SIADH and acts
by causing nephrogenic Diabetes insipidus.20 Other
more uncommon causes of hyponatraemia such as
cerebral salt wasting and sick cell syndrome should be
considered and is associated with a demonstrable
plasma osmolar gap. 
In this study, 7.7% patients had sodium corrected at
a rate of >15 mmol/L/24 hours and at a rate of 10 to
15 mmol/L/24 hours in another 9.5%. This, however,
may prove to be detrimental to the patient and correction
be done at a properly  adjusted rate.
There has also been controversy regarding the rate of
correction of hyponatraemia due to the risk of
development of CPM (central pontine myelinosis) if
rapid correction of hyponatraemia is undertaken. Arieff
advocates rapid correction within certain defined
parameters. Sterns recommends a more conservative
approach.5,10 However, a moderate approach should be
adopted as suggested by Ellis21 at a rate of correction of
less than 10 mmol/L in 24 hours.16 Hojer22 suggested
that chronic hyponatraemia be corrected slowly at a rate
of 0.5 mmol/L/hour as the brain has adapted to the
hypotonic extracellular environment and rapid correction
in this case will lead to demyelination.17 In acute
hyponatraemia, there is a high risk of cerebral
oedema, therefore, rapid correction with hypertonic
saline preferably with a loop diuretic at a rate of
1-2 mmol/L/hour should be undertaken.4,8,22,23
Inadequate treatment of symptomatic hyponatraemia
may result in significant morbidity.24 There is a lack of
randomized controlled trial in this arena and this study
had the limitation of being a retrospective analysis with
incomplete documentation. Further studies need to be
carried out on a prospective basis, which may in turn
help to improve the clinical practice.
CONCLUSION
Hyponatraemia is a common electrolyte disturbance. It
can be well-diagnosed with a history of concurrent
illness and medications accompanied by an assessment
of extracellular volume on physical examination. This
needs to be accompanied by relevant biochemical
profile as the treatment given depends on the aetiology.
If hyponatraemia is inadequately investigated, the
management  instituted may actually be inappropriate
and inadequate. Management includes immediate
treatment in patients with acute severe hyponatraemia
because of risk of cerebral oedema and hyponatraemic
encephalopathy. Chronic hyponatraemia requires fluid
restriction and rapid correction needs to be avoided to
reduce the risk of central pontine myelinosis.
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